Tenaya Therapeutics, Inc. (TNYA)

Market Cap	157.37M +39.2%
Revenue (ttm)	n/a
Net Income	-90.60M
EPS	-0.59
Shares Out	217.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,696,931
Open	0.6900
Previous Close	0.6676
Day's Range	0.6899 - 0.7285
52-Week Range	0.3600 - 2.3500
Beta	2.99
Analysts	Strong Buy
Price Target	5.33 (+634.97%)
Earnings Date	May 6, 2026

About TNYA

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: TNYA
• Website: https://www.tenayatherapeutics.com

Analyst Summary

According to 3 analysts, the average rating for TNYA stock is "Strong Buy." The 12-month stock price target is $5.33, which is an increase of 634.97% from the latest price.

Price Target

$5.33

(634.97% upside)

Analyst Consensus: Strong Buy